Salicoside

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

水杨苷是一种从柳树皮中提取的酚 β-糖苷，具有抗炎作用。

Salicin is a phenol β-glycosid produced from willow bark that shows anti-inflammatory effects.(In Vitro):Significant down regulation of PGE2, the enzymatic product of COX2, to 76% in lysate and 70% in supernatant is observed with Salicin 10 μM treatment in COLO cells when compare to the COLO control. This is accompanied with a minimal COX1 inhibition to 91% of the CCD control on the genetic level. Treatment with Salicin 1 μM decreases colon cancer cell proliferation rates from 144% to 113% at 24 hours and 187% to 130% at 48 hours, with 10 μM decreasing proliferation rates to 108% at 24 hours and 119% at 48 hours. The concentrations of TNF-α, IL-1β and IL-6 of LPS-induced cells pretreated with 0.07, 0.14 and 0.28 μM Salicin are significant reduced compare with LPS group.(In Vivo):Salicin (D(-)-Salicin) (35, 70, 140 μM) markedly inhibits the LPS-induced pathological changes. MPO activity in LPS-induced lung tissue is significantly increased compare with control group. However, Salicin (35, 70, 140 μM) markedly inhibits this change. Pretreatment with Salicin inhibits LPS-induced activation of JNK, ERK, p38/MAPK and p65 in a dose-dependent manner.

Significant down regulation of PGE2, the enzymatic product of COX2, to 76% in lysate and 70% in supernatant is observed with Salicin 10 μM treatment in COLO cells when compare to the COLO control. This is accompanied with a minimal COX1 inhibition to 91% of the CCD control on the genetic level. Treatment with Salicin 1 μM decreases colon cancer cell proliferation rates from 144% to 113% at 24 hours and 187% to 130% at 48 hours, with 10 μM decreasing proliferation rates to 108% at 24 hours and 119% at 48 hours. The concentrations of TNF-α, IL-1β and IL-6 of LPS-induced cells pretreated with 0.07, 0.14 and 0.28 μM Salicin are significant reduced compare with LPS group.

Salicin (D(-)-Salicin) (35, 70, 140 μM) markedly inhibits the LPS-induced pathological changes. MPO activity in LPS-induced lung tissue is significantly increased compare with control group. However,Salicin (35, 70, 140 μM) markedly inhibits this change. Pretreatment withSalicin inhibits LPS-induced activation of JNK, ERK, p38/MAPK and p65 in a dose-dependent manner.

NSC 5751 | D-(-)-Salicin

Chromatin/Epigenetic

COX

COX

Other Indications

——

138-52-3

286.28

C13H18O7

>98% (HPLC)

Water: 24 mg/mL (83.83 mM); DMSO: 57 mg/mL (199.1 mM)

O[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@@H]1OC2=CC=CC=C2CO

alpha-Hydroxy-o-tolyl beta-D-glucopyranoside

(-20℃)

With Ice Pack

≥ 2 years